Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website: https://business.uoregon.edu/centers/lce

Clinical Trials

Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Colchicine 0.5 MG

First Posted Date: 2024-04-02

Last Posted Date: 2024-10-14

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 84

Registration Number: NCT06342609

Locations: 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance, California, United States

Study of Cannabidiol in Sanfilippo Syndrome

Phase 2

Not yet recruiting

Conditions: Sanfilippo Syndrome
Mucopolysaccharidosis III

Interventions: Drug: Placebo
Drug: Epidiolex

First Posted Date: 2024-03-27

Last Posted Date: 2025-03-19

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 35

Registration Number: NCT06333041

Locations: 🇺🇸
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States

Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection

Phase 2

Recruiting

Conditions: Bone Infection
Joint Infection
Bone and Joint Infection

Interventions: Drug: Omadacycline Pill
Drug: Standard of Care

First Posted Date: 2023-03-03

Last Posted Date: 2025-03-10

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 180

Registration Number: NCT05753215

Locations: 🇺🇸
The Lundquist Institute For Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States

Diet-induced Elevations in LDL-C and Progression of Atherosclerosis

Completed

Conditions: Hypercholesterolemia

First Posted Date: 2023-02-17

Last Posted Date: 2024-03-19

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 100

Registration Number: NCT05733325

Locations: 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute), Torrance, California, United States

Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

Phase 4

Recruiting

Conditions: Type II Diabetes
Atherosclerosis

Interventions: Drug: Tirzepatide
Drug: Placebo

First Posted Date: 2023-02-01

Last Posted Date: 2024-10-14

Lead Sponsor: Matthew J. Budoff

Target Recruit Count: 120

Registration Number: NCT05708859

Locations: 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute), Torrance, California, United States

Long Haul COVID Rehabilitation & Recovery Research Program

Not Applicable

Recruiting

Conditions: Post-Acute COVID-19 Syndrome

Interventions: Other: Virtual vs On Site Pulmonary Rehabilitation

First Posted Date: 2022-06-01

Last Posted Date: 2024-07-01

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 40

Registration Number: NCT05398692

Locations: 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States

Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke

Phase 2

Conditions: Acute Ischemic Stroke

Interventions: Drug: Dextrose in Water
Drug: Acetylcysteine

First Posted Date: 2021-06-09

Last Posted Date: 2021-06-11

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 118

Registration Number: NCT04918719

Prevention of Obesity in Infants of Overweight and Obese Women

Not Applicable

Conditions: Infant Obesity

Interventions: Other: Calibration of infant breast milk and formula milk intake

First Posted Date: 2021-03-04

Last Posted Date: 2022-02-22

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 240

Registration Number: NCT04782063

Locations: 🇺🇸
Penn State College of Medicine, Hershey, Pennsylvania, United States

Determine if Human Infant Weight Gain Can be Modulated to Prevent Obesity

Not Applicable

Not yet recruiting

Conditions: Obesity, Infant

Interventions: Other: Calibration of infant breast milk and formula milk intake

First Posted Date: 2020-08-26

Last Posted Date: 2023-07-10

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 100

Registration Number: NCT04526860

Locations: 🇧🇷
Breastfeeding Center Ana Abrao, Federal of São Paulo University, Brazil, Sao Paulo, San Paulo, Brazil

Comparison of Two Application Techniques for LET Gel

Phase 4

Completed

Conditions: Lacerations
LET
Pain, Procedural

Interventions: Drug: LET Lidocaine (4%), Epinephrine (0.1%), and Tetracaine (0.5%) topical gel

First Posted Date: 2019-12-18

Last Posted Date: 2021-02-18

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 48

Registration Number: NCT04203225

Locations: 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy